Cure My Disease

Don't miss your cure!

 Log in / Sign up

Boosting the immune system after transplant: could 'Killer' cells prevent relapse?

NCT ID NCT07692607

Disease control Sponsor: LucasBio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether giving patients their own specially grown immune cells (called cytokine-induced killer cells) shortly after a stem cell transplant is safe. The trial enrolls adults with lymphoma who are receiving a transplant of their own stem cells. Researchers will monitor side effects and check for viral infections over two years, while also tracking whether the cancer stays away.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cytokine-induced killer (CIK) cells
What this could lead to
If safe, CIK cells could become a standard addition to stem cell transplants, potentially lowering the chance of cancer returning.
What could go wrong
This is a small early safety study with only 25 participants, so it cannot prove effectiveness. There is a risk of side effects like infections or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Mar 2022

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients who meet all of the following criteria: 1. Patients aged 19 to 70 years. 2. Patients with lymphoma who are expected to undergo autologous hematopoietic stem cell transplantation. 3. Patients with the ECOG performance status scale of 0 or 1. 4. Patients with a life expectancy longer than 3 months. 5. Patients without evidence of an acute infectious disease. 6. Patients without evidence of a concomitant malignancy. 7. Individuals who have provided written consent to comply with the restrictions, either by themselves or through their legal guardians. Exclusion Criteria: 1. Female patients who are pregnant, breastfeeding, of childbearing potential, or not using appropriate contraceptive methods. 2. Patients with active infection or fever (≥38°C) of unknown etiology, or ongoing bacterial or fungal infection. 3. Patients aged below 19 years or above 70 years. 4. Patients with the ECOG performance status scale of 2, 3, or 4. 5. Patients who have been diagnosed with HIV, uncontrollable hypertension, unstable angina, congestive heart failure (NY class II or higher), uncontrollable severe diabetes, coronary angioplasty within the past 6 months, acute myocardial infarction or non-malignant disease, including uncontrollable atrial or ventricular fibrillation, within the past 6 months. 6. Patients with mental illness or drug intoxication that may affect the results of this clinical study. 7. Patients who are participating in another clinical study. 8. Patients deemed ineligible for participation in this clinical study by the investigator. 9. Patients with other severe medical conditions that may compromise compliance with the clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autologous hematopoietic stem cell transplant are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma Neoplasm, Residual viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autologous hematopoietic stem cell transplant

Contacts and locations

Locations

  • The Catholic University of Korea Seoul St.Mary's Hospital

    Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.